The latest Cooper Companies quarterly is out, and a few points...

The latest Cooper Companies quarterly is out, and a few points to note on Misight:

• Revenue was US$ 24.1M in the quarter, up 50% from the same period last year. So, even though revenue is now considerable, growth rate is being maintained, indicating strong market conditions
• Misight is on track to do just under $100M for CY24 in revenue.
• Misight now exceeds Ortho-k in revenue per quarter for Cooper, indicating soft contact lenses are winning over Ortho-k for families as the preferred treatment.
• Insurance coverage uptake is still slow, so a burst of growth from when the product becomes cheaper for families is still to come.
• China is still slow, so substantial growth potential there too.
  

All proof that the market exists, and growth for VTI could be strong once we gain FDA approval with a better product.

We could expect preliminary data on 2 years from the RCT within the next 6 weeks I reckon. If it remains as strong as at 1yr (50% more effective than MiSight), it will hopefully convince more ECPs now is the time to try.